Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
Osin
P
P
Crook
T
T
Powles
T
T
Peto
J
J
Gusterson
B
B
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics*; D006801:Humans; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen